Currently, no first dose COVID-19 vaccine appointments are available. For updates about the vaccines, visit beaumont.org/covid-vaccine.

Infectious Diseases Research

Beaumont Infectious Diseases strongly believes that our research needs to focus on studies which can impact patient care. We are a combination of a translational research laboratory that takes studies from bench to bedside and a clinical trials unit which implements those studies in patients.

Our patients are the reason we perform research, everything we do is with the goal of improving the diagnosis and treatment of infections and patient outcomes. We focus on a number of specific pathogens which are designated as high or urgent threat level by the CDC including:

  • Acinetobacter baumanii
  • Pseudomonas aeruginosa
  • Candida albicans
  • E. coli
  • C. difficile
  • MRSA

Clinical research is a cooperative effort between our physicians in Infectious Disease and laboratory faculty in Clinical Microbiology. Currently, there are about 15 active clinical trial within Infectious Diseases. These studies involve the use of novel diagnostics, novel antibiotics, new uses for existing antibiotics, antibiotic prophylaxis, probiotics, and the microbiome.

Laboratory researchers are working on various projects including novel diagnostics, antibiotic resistance, antibiotic allergies, antifungal treatment, and differences among strains of pathogenic bacteria.


Areas of research

  • Antibiotic resistance
  • Diagnostics
  • Antifungal therapy
  • C. difficile
  • MRSA
  • The microbiome
  • Host genomics and risk of infection
  • Antibiotic utilization and stewardship
  • Improved antibiotic activity